Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22165358 | 1.00 | MAPK8 (0.33) | MAPK8MAPK9GABBR2GABBR1MERTK | |
| SCHEMBL22171130 | 0.81 | MERTK (0.30) | MERTK | |
| SCHEMBL22171345 | 0.80 | KDM4E (0.30) | — | |
| SCHEMBL13734226 | 0.78 | MAPK8 (0.44) | MAPK8MAPK9MEN1KMT2AGSK3A | |
| SCHEMBL13735566 | 0.77 | MAPK8 (0.57) | MAPK8MAPK9MEN1KMT2AALDH1A1 | |
| SCHEMBL24618927 | 0.77 | MAPK8 (0.33) | MAPK8MAPK9GABBR2GABBR1MERTK | |
| SCHEMBL30801506 | 0.77 | KDM4E (0.38) | MAPK8MAPK9GABBR2GABBR1MERTK | |
| SCHEMBL22860597 | 0.77 | HTT (0.44) | MAPK8MAPK9GABBR2GABBR1MERTK | |
| SCHEMBL13736418 | 0.77 | KDM4E (0.38) | MAPK8MAPK9GABBR2GABBR1MERTK | |
| SCHEMBL30597068 | 0.76 | MERTK (0.37) | MAPK8GABBR2GABBR1MERTKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346618-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4069697-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120020135-A | Pyrimidinone derivative and application thereof in medicine | 康百达（四川）生物医药科技有限公司 | 2025-05-20 | — | — | CN | disclosed |
| EP-3709426-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ENERGY DEVICE USING SAME | MITSUBISHI CHEM CORP (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024118960-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-111344891-B | Nonaqueous electrolyte and energy device using same | 三菱化学株式会社 | 2023-05-02 | — | — | CN | disclosed |
| US-11631895-B2 | Nonaqueous electrolyte solution and energy device using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-04-18 | — | — | US | disclosed |
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4069697-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| EP-3993802-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114340634-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | MAPK8 1966/4885MAPK9 2508/4885GABBR2 1759/4885 |
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | CRHR1, CRH, CRHR2 | MAPK8 2595/4885MAPK9 3632/4885GABBR2 193/4885 |
| US-11631895-B2 | Nonaqueous electrolyte solution and energy device using same | SLC26A3, VDAC3, SLC25A13 | MAPK8 1830/4885MAPK9 1456/4885GABBR2 4405/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | MAPK8 1966/4885MAPK9 2508/4885GABBR2 1759/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MAPK8 221/4885MAPK9 166/4885GABBR2 4672/4885 |
| US-20250346618-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OPRD1 | MAPK8 2541/4885MAPK9 1676/4885GABBR2 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.